Drug access extended for cancer patients already seeing benefits
NCT ID NCT01742299
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 32 times
Summary
This study provided continued access to imatinib for 155 patients with gastrointestinal stromal tumors (GIST) or chronic myeloid leukemia (CML) who were already benefiting from the drug in a previous Novartis trial. The main goal was to track long-term safety and ensure patients could keep receiving treatment as long as their doctor felt it was helping. It was not designed to test new effects, but to support ongoing care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST AND CML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Novartis Investigative Site
Nanjing, Jiangsu, 210002, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200433, China
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Pessac, 33604, France
-
Novartis Investigative Site
Poitiers, 86021, France
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Cluj-Napoca, Cluj, 400015, Romania
-
Novartis Investigative Site
Bucharest, 022328, Romania
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Basel, 4031, Switzerland
-
Novartis Investigative Site
Bangkok, 10700, Thailand
-
Novartis Investigative Site
Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
-
Novartis Investigative Site
Sutton, Surrey, SM2 5PT, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Sidney Kimmel CCC At JH
Baltimore, Maryland, 21231, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
Weill Cornell Medical Center
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.